AP-096 (adalimumab biosimilar) / Aprogen - LARVOL DELTA

Aprogen announced on the 12th that it is accelerating the global development of biosimilars and new drug pipelines, expanding CMO (consignment production) and CDMO (consignment development production) capabilities, and speeding up the leap forward of global bio companies (Maeil Business Newpaper) - "In particular, as major pipelines such as Herceptin and Humira biosimilars and immuno-cancer drugs 'PMC-309' are materialized, expectations for copyright contracts and licenses are growing in the future....Herceptin biosimilar 'AP-063' has reorganized its development strategy in line with changes in the global regulatory environment....Humira biosimilar 'AP-096' is also in the final stages of preparation for entering the global market."

Commercial • Breast Cancer • Colorectal Cancer • Melanoma • Mesothelioma